Abstract Urothelial carcinoma of the bladder and upper tract pose significant diagnostic and therapeutic challenges. White light endoscopy plays a central role in the management of urothelial carcinoma but has several wellrecognized shortcomings. New optical imaging technologies may improve diagnostic accuracy, enhance local cancer control, and better stratify treatment options. Confocal laser endomicroscopy enables dynamic imaging of the cellular structures below the mucosal surface and holds promise in providing real time optical diagnosis and grading of urothelial carcinoma. A variety of imaging probes are available that are compatible with the full spectrum of cystoscopes and ureteroscopes. We review the underlying principles and technique of confocal laser endomicroscopy in the urinary tract, with emphasis on specific application towards urothelial carcinoma. While the available data are largely related to urothelial carcinoma of the bladder, the lessons learned are directly applicable to the upper tract, where the clinical needs are significant. Ongoing efforts to optimize this technology offer an exciting glimpse into future advances in optical imaging and intraoperative image guidance.
Introduction
Urothelial carcinomas are common cancers that pose significant management challenges and healthcare burdens. Urothelial carcinoma of the bladder (UCB) accounts for >95 % of bladder cancer, which ranks as the sixth most common cancer in the US, with 74,690 new cases and 15,580 deaths expected in 2014 [1, 2] . UCB is a heterogeneous disease, ranging from low-grade cancer that does not recur after initial resection, to high-grade variants that progress to metastatic, lethal disease [3] . Approximately 80 % of UCB is non-muscle-invasive at initial diagnosis, while the remaining presents with muscle-invasive or metastatic cancer [4] . UCB recurrence is among the highest of all cancers, reaching up to 61 % at one year and 78 % at five years [5] , thereby requiring costly lifelong surveillance [4, 6] . In comparison, upper tract urothelial carcinoma (UTUC) appears histologically indistinct from UCB and accounts for 5-10 % of all urothelial carcinomas [7] . Studies have shown that 8 to 13 % of UTUC is present with concomitant UCB [8, 9] , and 15-50 % of patients treated for UTUC go on to manifest recurrence in the bladder [10] .
Direct visualization of the urothelium via endoscopy is integral in the management of urothelial carcinoma. In the bladder, white light cystoscopy (WLC) is used in the initial diagnosis and subsequent surveillance to determine tumor size, number, and location. Despite its central role, WLC has well-documented limitations [11, 12] . Visualization of papillary tumors is straightforward, but differentiation of nonpapillary or flat carcinomas, such as carcinoma in-situ (CIS), from benign inflammatory lesions are frequently challenging [11, 13•] . Several studies have shown that only 58-68 % of CIS are detected by WLC [14] [15] [16] . WLC also guides transurethral resection (TUR) and local staging of UCB. Indistinct borders and difficulty in visualizing submucosal tumor margins, however, may lead to incomplete tumor resection [17] .
The presence of multifocal lesions further increases the likelihood that some will go undetected on initial TUR, and indeed, 'residual' cancer can be found in 40 % of patients at the time of second TUR [18, 19] . Unrecognized and incompletely resected tumors, in addition to growth of microscopic lesions to detectable sizes, cancer cell implantation, and new growth from aggressive tumors, all contribute to the high recurrence rate of UCB [20, 21] . Given the suboptimal detection of cancerous lesions using WLC, there is considerable interest in developing adjunctive imaging modalities to improve the effectiveness of WLC and TUR.
Ureteroscopy and ureteroscopic biopsy are the standards in establishing the initial diagnosis of UTUC, and radical nephroureterectomy with bladder cuff excision remains the standard for definitive treatment [22] . Despite significant advances in endourology over the last 20 years, ureteroscopic biopsy remains technically challenging with suboptimal yield. Recognized shortcomings include insufficient tissue quantity for histology, sampling variability from heterogeneous lesions, tumor under-grading, and lack of staging information [23] [24] [25] . Up to 25 % of renal pelvic or ureteral biopsies may be nondiagnostic due to insufficient quantities of tissue [26] . In addition, 15 % of UTUC found to be low grade from ureteroscopic biopsy are up-graded after nephroureterectomy [24, 25] . In patients with solitary kidney, bilateral UTUC, and severe underlying renal disease, nephroureterectomy may be contraindicated. These challenging clinical scenarios, coupled with advances in endourology, have encouraged the investigation of alternative strategies of UTUC treatment [27] . For selected patients with UTUC (i.e., low grade), renal-sparing endoscopic management based on ablation has become a viable option, with cancer-specific survival rates comparable to nephroureterectomy [28, 29] . Taken together, these studies highlight the need for improved optical diagnosis for UTUC, particularly to better stratify patients for renal-sparing treatment options, as well as for long-term endoscopic surveillance.
To address the shortcomings of standard white light endoscopy, numerous optical imaging technologies are under active investigation for applications in the urinary tract [12, 30] . The primary goal of these new strategies is to better identify and characterize urothelial pathology beyond white light. Imaging technologies are classified based on field of view. Macroscopic imaging modalities survey a large area of mucosa similar to white light endoscopy, and provide additional contrast enhancement to highlight suspicious lesions and distinguish them from surrounding non-cancerous mucosa. Examples include photodynamic diagnosis (PDD) (i.e., fluorescence cystoscopy, blue light cystoscopy) for the bladder and narrow band imaging (NBI) for the bladder and upper tract. Microscopic modalities are commonly referred to as optical biopsy technologies that are capable of high-resolution, subsurface characterization of suspected lesions. With optical biopsy, information is provided on tissue microarchitecture and cellular morphology that is not possible with macroscopic imaging. Examples include optical coherence tomography (OCT), spectroscopy, and confocal laser endomicroscopy (CLE), which is the focus of the current review.
Confocal Laser Endomicroscopy: Principles
CLE is based on confocal microscopy, a mainstay tool of basic science research for high-resolution cellular and subcellular imaging. Recent advances in fiber-optics technology have enabled packaging of a confocal microscope into a small probe format compatible with standard endoscopes ( Fig. 1) [31•] . A 488 nm low-power laser scans a tissue section of interest below the surface. The tissue is nonspecifically stained with fluorescein, a Food and Drug Administration (FDA)-approved contrast agent that can be administered intravenously or topically [32] . Under excitation, the fluorescein emits light that is filtered through a pinhole so that only in-focus light is measured by a photodetector while the out-of-focus light is rejected, resulting in optical sectioning of the regions of interest with micron-scale resolution comparable to histology [31•] . In contrast to standard hematoxylin and eosin (H&E) histology, nuclear features are not routinely visualized, since fluorescein highlights the extracellular matrix and does not cross intact cell membranes. CLE images are acquired as video sequences at a rate of 12 frames per second via direct contact of the probe with tissues of interest.
A probe-based CLE system (Cellvizio, Mauna Kea Technologies) is available clinically and is approved for gastrointestinal endoscopy and bronchoscopy [32, 33] . Since the initial ex vivo and in vivo feasibility studies in 2009 [31•, 34] , CLE has been under investigation in the urinary tract. CLE recently received approval for applications in the bladder and upper tract in Europe and the US. Imaging probes are available, ranging from 0.85 to 2.6 mm in diameter with varying optical specifications in spatial resolution, field of view, and compatibility with existing endoscopes (Fig. 2) . The 2.6 mm probe is compatible with the working port of standard 22 French (Fr) or larger cystoscopes and resectoscopes, while the 1.4 mm probes are compatible with the larger scopes, as well as the working channel of flexible cystoscopes (~15 Fr). The newest 0.85 mm probe is compatible with all standard scopes for the lower and upper urinary tracts. CLE is best implemented for in-depth characterization of the tissue of interest after an initial, broad-based survey with WLC or other wide field technologies such as fluorescence cystoscopy or narrow band imaging. The small field of view is offset by the ability of CLE to visualize microscopic, cellular features and tissue organization that approach the characterization seen upon H&E histology, the current standard for cancer diagnosis. Given the in vivo characterization, CLE offers the added benefit of real-time imaging of physiological parameters, including vascular blood flow that is not possible with H&E [13•] .
Technical Considerations
The technique of CLE in the lower urinary tract has been described in a step-by-step video [35•] . In the bladder, fluorescein can be delivered intravesically with a urinary catheter using 300-400 ml 0.1 % fluorescein diluted in saline, or intravenously with a 0.5 ml 10 % fluorescein injection. Intravenous fluorescein is FDA-approved for use in diagnostic angiography of the retina. It has also recently been shown to be a safe, nontoxic contrast agent for CLE in the gastrointestinal tract. In over 2,000 patients undergoing CLE operations, IV fluorescein was administered and shown to be well tolerated, with no serious adverse events reported. Patients experienced temporary yellow skin discoloration lasting a couple of hours, as well as other minor side effects, including transient hypotension without shock, nausea, injection site reaction, diffuse rash, and mild epigastric pain [36] . Moreover, prior work done by our group on CLE in the urinary tract has shown that both IV and intravesical fluorescein demonstrate excellent safety profiles, with transient fluorescently tinged urine as the primary minor side effect [31•] .
Intravesical fluorescein is left indwelling for 5 min to allow uptake of the dye in the mucosa, whereas IV fluorescein distributes rapidly and can be administered within 1 minute before CLE imaging [13•] . Both intravesical and IV fluorescein enables visualization of papillary tumors, flat tumors, erythematous patches, and the border between normal mucosa and neoplastic lesions. Observation of the resection bed as well as the prostatic and penile urethra requires IV fluorescein administration. Following imaging, the CLE probes can be sterilized and reused.
The majority of the published work to date has been done using the 2.6 mm probe. As previously mentioned, WLC is first used for general surveillance of the bladder, followed by detailed imaging with CLE at specific regions of interest. Increasing and decreasing the pressure of the probe against the bladder surface enables sectional visualization of varying depths of mucosa. Biopsies of suspicious lesions are taken and sent for histopathologic analysis and postoperative comparison with acquired CLE images [35•] . Due to the narrow field of view of CLE, post-processing of the images involves a video mosaicing technique that can stitch together overlapping, serial frames into a static, composite piece. This image reconstruction method can expand the field of view up to fivefold and remove motion distortions and artifacts without sacrificing resolution, providing a more complete view of the imaged tissue for analysis [13•, 37] .
Imaging Diagnostic Criteria for Bladder Cancer
Prior works by our group have established a preliminary set of optical diagnostic criteria for normal urothelium, benign inflammatory lesions, low-grade tumors, and high-grade tumors [13•, 31•, 38•] . Characteristic microarchitectural (flat vs. papillary, tissue organization, and vasculature) and cellular (morphology, cohesiveness, borders) features for each tissue type have been described [38•] . Representative images documenting the various diagnostic constituents have been compiled into an optical imaging atlas in an ongoing effort to refine the diagnostic criteria (Fig. 3) . Notably, given the limited depth of penetration, CLE is unable to visualize the muscularis propria from the muscosal surface [31•] . It is, however, possible to image the muscularis propria (and perivesical fat) after tumor resection through IVadministration of fluorescein or secondary instillation of topical fluorescein.
Under CLE, normal mucosa is characterized by layers of superficial, polygonal-shaped umbrella cells and homogeneous, smaller intermediate cells located more deeply. Within the lamina propria, dense capillary networks are commonly seen populated with flowing erythrocytes (Fig. 3) . These elements of normal morphology are absent in cancerous lesions (Fig. 4) . Low-grade papillary tumors demonstrated crowding of monomorphic cells, papillary structures, and the presence of fibrovascular stalks, vessels with a thickened endothelial layer (Fig. 4a) . High-grade tumors are identified by a decidedly disorganized appearance, with pleomorphic cells arranged haphazardly around distorted vasculature. Delineating cell boundaries has proven difficult given the general loss of cellular cohesion and tissue organization in high-grade tumors (Fig. 4b) . In benign, inflammatory urothelium, small monomorphic cells are observed loosely distributed in the lamina propria, but fibrovascular stalks are notably absent (Fig. 4c) .
High-grade carcinomas can appear as papillary, sessile, and flat. Importantly, flat lesions typified by high-grade CIS are difficult to diagnosis under WLC, given its close mimicry to erythematous patches of benign, inflammatory origin. Under H&E histology, CIS is known to be a heterogeneous entity, with different morphological features and a degree of inflammatory infiltrate [39] . As seen in Fig. 5 , CIS appears as pleomorphic cells with indistinct cellular borders and absence of organized microarchitecture. Given the heterogeneity of CIS, additional evaluation is catalog optical imaging characteristics for CIS with histopathological correlation. Computeraided imaging diagnosis may prove to be helpful, as described in CLE applications in the gastrointestinal (GI) tract [40] .
Inter-Observer Variance and Diagnostic Accuracy
Novel imaging technologies necessitate inter-observer agreement studies to evaluate variability among observers in interpreting acquired images. High precision in a diagnostic test indicates reproducibility of results and reliability for consistent analysis [41] . This in turn predicts the value of the imaging modality for clinical applications. Endoscopic diagnosis and grading of cancers using CLE imaging demonstrate short learning curves as well as good to substantial interobserver agreement in colorectal cancers [42, 43] , and substantial to excellent agreement in Barrett's esophagus [44] [45] [46] . Most recently, inter-observer agreement in CLE image interpretation of bladder cancers was determined to range from moderate in novice CLE users to substantial in expert observers [38•] . CLE is therefore a highly adoptable technology for the diagnosis of various cancers. Using bladder cancer as a model with CLE, current work is focused on expanding this technology into related urologic cancers. Measures of accuracy using CLE has a sensitivity of 88-98 %, specificity of 92-96 %, and accuracy of 92-97 % in Barrett's esophagus and gastrointestinal neoplasia [40, 45] . Diagnostic accuracy of within perivesical fat, and copious red blood cells. The resection bed was imaged after the tumor resection. In the upper urinary tract, images of the urothelium are similar to the lower tract. Images of the lower urinary tract were acquired in vivo while those of the upper urinary tract were obtained ex vivo. Video mosaicing was utilized to expand the field of view for select images Fig. 4 Diagnostic imaging criteria for urothelial carcinoma. a) Lowgrade cancer are characterized by organized, densely-packed, monomorphic cells, the absence of umbrella cells, papillary structures, and fibrovascular stalks. b) High-grade cancer show disorganized, pleomorphic cells, indistinct borders with loss of cellular cohesion, the absence of umbrella cells, and fibrovascular stalks with distorted vasculature. c) Benign, inflammatory lesions feature small, infiltrative, monomorphic cells in the lamina propria loosely arranged and absent fibrovascular stalks. Normal urothelium is described in Fig. 3 . Using confocal laser endomicroscopy adjunct to white light cystoscopy, these diagnostic imaging criteria demonstrated substantial agreement among urologists familiar with the technology (ĸ 0.80) and moderate agreement among novice users (ĸ 0.59). Sensitivity and specificity of the diagnostic criteria were reported as 89 % and 88 %, respectively bladder cancer using WLC together with CLE, as clinically relevant, has been reported as having 89 % sensitivity and 88 % specificity [38•] .
CLE in the Upper Tract
Previously, ex vivo CLE imaging of the renal pelvis and proximal ureter showed similarity between upper tract and bladder urothelial cells and lamina propria (Fig. 3) [13•] . With the recent availability of a 0.85 mm imaging probe compatible with standard semirigid and flexible ureteroscopes (Fig. 6) , our group has initiated a feasibility study of CLE in the upper urinary tract [47] . With IV administration of fluorescein, normal urothelium and papillary UTUC have been imaged with CLE. Imaging of UTUC showed characteristic features of tumors, including papillary structure, pleomorphic cells, and fibrovascular stalks. In comparison to the 2.6-mm probe, the 0.85-mm probe expectedly demonstrated lower resolution in identifying diagnostic features in the bladder. Additional works are pending to expand this initial feasibility study.
Future Outlooks
Optical diagnosis of urothelial carcinoma using CLE, while promising, remains at the early stage of clinical integration. Recent approval for clinical use will facilitate prospective multicenter studies to validate the clinical efficacy and determine optimal clinical indications. In UCB, outstanding questions include diagnostic accuracy of CLE for papillary and non-papillary tumors, clinical utility of resection bed imaging after TUR, and to determine the role of CLE in bladder cancer surveillance. In UTUC, additional clinical experience is needed to investigate the feasibility of the 0.85 mm probe.
To decrease the learning curve and facilitate clinical studies, the development of a computer-based 'smart atlas' for urothelial carcinoma may be beneficial through collaborative efforts among urology, pathology, and imaging scientists. Wu et al. have established the basis for an optical imaging atlas of bladder cancer, with representative images describing the various grades acquired from CLE [13• ]. An exciting avenue for future work involves expanding the bladder cancer atlas into an automated smart atlas to broaden the range of users who would benefit from this evolving technology. André et al. have pioneered this in the GI tract, with the development of a content-based, image retrieval classification algorithm that matches real-time CLE images with those stored in the database. The goal is to provide objective assistance in the diagnosis of colonic polyps, and initial results are promising [48, 49] . Such a system would naturally develop into a more accurate tool with the addition of more CLE images to the source database, detailing the various morphologies and appearances of colorectal lesions.
Moreover, an attractive feature of CLE is the ease with which it integrates into surgical practice, given its compatibility with existing endoscopes. This advantage can be further harnessed using molecular imaging to target tissues of interest. Though fluorescein is currently the preferred contrast agent for CLE, it is a nonspecific dye that broadly stains the extracellular matrix, with diffuse uptake in both normal and neoplastic tissues. Conjugating monoclonal antibodies to fluorescein isothiocyanate for targeted binding of cancer-specific antigens has the potential to significantly improve tumor detection. The potential immunogenic responses to antibodies will need to be investigated [50] [51] [52] . Peptides, which are less immunogenic and smaller in size, may be more favorable. In contrast to IV fluorescein, topical application of fluorescent peptides can reduce inter-observer subjectivity in image interpretation and guard against incomplete tumor resection by demarcating tumor boundaries [50] . Additionally, the high affinity and selectivity of fluorescent peptide probes to cancer cell receptors reduces the amount of the agent needed for imaging, augmenting image quality by increasing the signal-to-noise ratio [51] .
Preclinical and early clinical studies of colorectal cancer demonstrated significantly greater signal in cancer cells over normal mucosa when a fluoresceinconjugated peptide marker specific for dysplastic colonocytes was administered [50, 53] . Similarly, a fluorescently labeled peptide used in imaging for esophageal adenocarcinomas revealed a 3.8-fold increase in signal intensity as compared to Barrett's esophagus or normal epithelium [52] . Preclinical studies evaluating a fluorescently labeled deoxyglucose agent for CLE detection of Barrett's esophagus capitalizes on the metabolic changes that occur with cancer and shows high sensitivity and specificity for differentiating between metaplastic and neoplastic sites [54] . These preliminary results suggest a logical path of exploration to enhance the detection and diagnosis of urothelial carcinoma using CLE and contrast agents with molecular specificity.
Conclusion
The advent of novel imaging technologies has a transformative potential in cancer detection and management. For urothelial carcinomas, confocal laser endomicroscopy has become one of the leading candidates as an adjunctive imaging modality to WLC to improve endoscopic visualization of tissues. Studies have demonstrated the reliability of CLE in bladder cancer diagnosis and the general adoptability of the technology. Recently, application of CLE has extended to optical imaging of the upper urinary tract as well. With efforts under way to increase the usability of this tool through the development of a smart atlas and targeted molecular probes, CLE promises to achieve better surgical outcomes and more effective management for patients with urothelial carcinoma.
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